Ibogaine, a naturally occurring psychoactive substance derived from the root bark of the African shrub Tabernanthe iboga, has been gaining attention for its potential to treat addiction and facilitating profound…
Ibogaine, a psychoactive indole alkaloid found in the West African shrub Tabernanthe iboga, has gained recognition for its potential in treating substance use disorders (SUDs). It has a historical background…
MDMA-assisted therapy has shown significant promise in the treatment of various psychiatric disorders, including post-traumatic stress disorder (PTSD), depression, and anxiety. This article provides an overview of the best practices…
There has been a recent increase in interest in MDMA therapy as Lykos Therapeutics intends to launch MDMA as a licensed medicine towards the end of 2024. This marks a…
In 6 months (around June 2024) the FDA (US medicine regulator) will likely approve MDMA (ecstasy) as a licensed medicine in the US. This will present a pivotal moment for…
Note: As of October 2023, psilocybin remains a Class A drug in the UK. The following article provides informational content and does not endorse or encourage illegal activities. Always adhere…
Introduction Ketamine, once primarily known as an anaesthetic agent, is gaining traction in Australia as a potential breakthrough treatment for mental health conditions. With the rise of ketamine clinics across…
As of the last update of this article in October 2022, psilocybin remains a Class A drug in the UK, making it illegal to produce, supply, or possess. The following…
Esketamine is a medication that is used to treat treatment-resistant depression (TRD) in adults. It is a form of ketamine, which is a general anaesthetic that has been shown to…
In the United Kingdom, ketamine is a licensed medication that is sometimes used in the treatment of depression. It is typically used as a "second line" treatment, meaning that it…